Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.72017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 11.06.2026. Verfasst von Darren R Feldman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Palliative Care, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, BioNTech.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Patients with relapsed/refractory (R/R) testicular germ cell tumor (GCT) progressing after salvage chemotherapy only have palliative therapeutic options. Real‐world data on this population are needed.
Methods
Adult men with testicular GCT receiving palliative chemotherapy in the United States were identified in the Komodo Research Database (01/2016–03/2023; index date = date of palliative chemotherapy initiation). Treatment patterns were analyzed for patients with continuous health plan enrollment from diagnosis to index date. Clinical outcomes (time to real‐world progression [TTrwP] and real‐world overall survival [rwOS]) were assessed among patients with prior salvage chemotherapy using the Kaplan–Meier method.
Results
In the treatment pattern analysis ( N = 51; median age 32 years), median (interquartile range) time from diagnosis to first‐line treatment was 0.9 (0.5–2.1) months, and to palliative chemotherapy was 12.5 (9.0–16.8) months. Index palliative chemotherapy regimens included gemcitabine‐oxaliplatin (37.3%), oral etoposide (15.7%), and gemcitabine‐oxaliplatin‐paclitaxel (15.7%). Prior to palliative chemotherapy, 33 patients (64.7%) received salvage chemotherapy. In the clinical outcome analysis ( N = 80; median age: 33 years), 49 (61.3%) patients were exposed to high‐dose chemotherapy (HDCT; ±conventional‐dose chemotherapy [CDCT]) and 31 (38.8%) only to CDCT. Overall median (95% confidence interval [CI]) TTrwP was 3.8 (2.6–4.7) months, 3.5 (2.3–4.7) months after HDCT±CDCT, and 4.0 (1.7–6.6) months after only CDCT, and median (95% CI) rwOS was 7.7 (6.3–9.6) months, 6.4 (5.6–9.6) months, and 9.3 (7.5–22.0) months, respectively.
Conclusions
Real‐world data captured heterogeneous treatment patterns and poor outcomes for patients with R/R testicular GCT receiving palliative chemotherapy, highlighting the need for novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Analysis Group, Inc., Quebec, Canada.
- BioNTech, Cambridge, Massachusetts, USA.
ORCID-Profile: Jessica Maitland
Förderung
- NCI NIH HHS
- BioNTech
Zitieren
APA
Feldman, D. R., Gagnon-Sanschagrin, P., Maitland, J., Yokoji, K., Guérin, A., Guan, V., & Joseph, G. (2026). Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72017
Vancouver
Feldman DR, Gagnon-Sanschagrin P, Maitland J, Yokoji K, Guérin A, Guan V, et al. Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72017
BibTeX
@article{Feldman2026,
author = {Feldman, Darren R and Gagnon-Sanschagrin, Patrick and Maitland, Jessica and Yokoji, Kana and Guérin, Annie and Guan, Victoria and Joseph, George},
title = {Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.72017}
}
EUVIMED